{'fraction_non_alphanumeric': 0.06373762376237624, 'fraction_numerical': 0.04888613861386139, 'mean_word_length': 4.575862068965518, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Long-Term Effect of Insulin Treatment in Cystic Fibrosis-Related Diabetes

Background: Although insulin treatment confers short-term benefit in cystic fibrosis-related diabetes (CFRD), few studies have compared its long-term effect on the clinical outcome. Objectives: In this study, we aimed to investigate the long-term impact of insulin treatment on pulmonary function, nutritional status and hospital admissions in patients with CFRD. Methods: We reviewed pulmonary function, body mass index (BMI) and hospital admissions 5 years before and 3 years after insulin therapy in 42 adult CFRD patients. Results: Prior to treatment, over a period of 5 years, the annual rate of change in forced expiratory volume in 1 s (FEV1) was –3.2%, forced vital capacity (FVC) –2.5%, and BMI –0.07%. At treatment of CFRD (baseline), the mean FEV1 was 51.6% predicted (range 24–96), FVC 66.4% (range 29–103) and BMI 19.5 (range 15.3–29.5). At 3 months following insulin treatment, there was a significant improvement in all parameters, which was maintained at 1 year for FEV1 (55.1%; p < 0.002), 2 years for FVC (72.1%; p < 0.01) and at 3 years for BMI (20.4%; p < 0.002). After 3 months, FEV1 declined at a rate similar to that before treatment (–3.2 vs. –3.1% per year; p = 0.77), such that the mean FEV1 after treatment returned to pretreatment baseline values at 34 months. There was no difference in the number of hospital admissions with insulin treatment. Conclusions: Insulin enhances the nutritional state and temporarily improves pulmonary function in CFRD patients, on average delaying the decline in FEV1 by 34 months.